However, one should be aware that due to the PD‐1/PD‐L1 pathway blockage during the course of ICB treatment, normal tissues may get damaged manifesting as immune‐related adverse effects, which could be further studied with a variety of indicators, for example, the biomarkers associated with cellular damage.[67] About 5 months post combination therapy, the mice with complete tumor regression in the RP phage + αPD‐1 group were challenged with MC‐38 tumor cells, none of them developed tumors 50 days post tumor inoculation (Figure S16, Supporting Information). This evidence concerns the gene PDCD1 and neoplasm.